NCT01927913 is a Phase 2 clinical trial of SPD602 in Transfusional Iron Overload, sponsored by Shire.

Who is sponsoring NCT01927913?

NCT01927913 is sponsored by Shire.

What drugs are being tested in NCT01927913?

Interventions in NCT01927913: SPD602, Deferasirox.

What condition does NCT01927913 study?

NCT01927913 studies Transfusional Iron Overload, Iron Overload, Iron Chelation, Beta-thalassemia, Transfusional Hemosiderosis, Iron Metabolism Disorders, Metabolic Diseases.

Is NCT01927913 still recruiting?

NCT01927913 is currently withdrawn. Last updated 2 June 2021.

Last reviewed 2021-06-02 · How we verify

NCT01927913

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Treatment of Iron Overload Requiring Chelation Therapy

Withdrawn Phase 2 Last updated 2 June 2021

What this trial tests

Phase 2 trial testing SPD602 in Transfusional Iron Overload. Withdrawn.

Timeline

20 November 2014

Primary endpoint
30 October 2015

30 October 2015

Quick facts

Lead sponsor	Shire
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Start date	20 November 2014
Primary completion	30 October 2015
Estimated completion	30 October 2015

Drugs / interventions tested

SPD602 — full drug profile →
Deferasirox (DEFERASIROX) — full drug profile →

Conditions studied

Transfusional Iron Overload — all drugs for Transfusional Iron Overload →
Iron Overload — all drugs for Iron Overload →
Iron Chelation — all drugs for Iron Chelation →
Beta-thalassemia — all drugs for Beta-thalassemia →

Sponsor

Shire — full company profile →

Who can join

18 and older, any sex, with Transfusional Iron Overload or Iron Overload. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this open-label study is to assess liver iron concentration using MRI imaging in subjects with beta-thalassemia when administered with either SPD602 or deferasirox for the treatment of chronic transfusional iron overload.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

2015 Clinical trials update in sickle cell anemia.
Archer N, Galacteros F, Brugnara C. · · 2015 · cited 25× · PMID 26178236 · DOI 10.1002/ajh.24116
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
Sadaf A, Hasan B, Das JK, Colan S, et al · · 2018 · cited 13× · PMID 29998494 · DOI 10.1002/14651858.cd011626.pub2
Calcium channel blockers for preventing cardiomyopathy due to iron overload in people with transfusion-dependent beta thalassaemia.
Padhani ZA, Gangwani MK, Sadaf A, Hasan B, et al · · 2023 · cited 5× · PMID 37975597 · DOI 10.1002/14651858.cd011626.pub3

Verify or expand the search:

Other trials of SPD602

Trials testing the same drug.

NCT01604941 — Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy · Phase 2 · terminated
NCT01363908 — Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload · Phase 2 · terminated

Other Shire trials

Trials by the same sponsor.

NCT05067868 — A Study of Replagal in Children and Adults With Fabry Disease in India · Phase 4 · recruiting
NCT03878953 — A Clinical Study of rhPTH(1-84) Treatment in Japanese Participants With Chronic Hypoparathyroidism · Phase 3 · withdrawn
NCT04840667 — A Study of Replagal in Treatment-naïve Adults With Fabry Disease · Phase 3 · terminated
NCT04429984 — Post Marketing Surveillance (PMS) Study for Velaglucerase Alfa (VPRIV) in India · completed
NCT04440488 — ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) Study · Phase 4 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01927913 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shire
Last refreshed: 2 June 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01927913.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing